Fournier Gangrene
11
1
1
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (11)
FATAL-NSTI Study (Factors Associated With In-hospital mortALity in NSTI).
Necrotizing Soft Tissue Infections
The Immunological Differences Between Fournier Gangrene and Perianal Abscess
SKin and Soft Tissue Necrotizing INfections in the Intensive Care Unit: a Prospective Multi-national Cohort Study
Management of Fournier Gangrene at Ibn Rochd University Hospital Center
Fournier's Gangrene in Patient With Uncontrolled Type 2 Diabetes
Modulation of Biomarkers in Patients With Flesh-eating Bacterial Infections After With Hyperbaric Oxygen Treatment
Prognosis and Treatment of Necrotizing Soft Tissue Infections: A Prospective Cohort Study
Fournier's Gangrene and the Origin of the Infection as a Prognostic of Morbidity and Mortality, an Analysis of 121 Patients
Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial
Biomarkers in Patients With Flesh-eating Bacterial Infections